L&K Biomed Ltd. (KOSDAQ:156100)

L&K Biomed Statistics

Total Valuation

L&K Biomed has a market cap or net worth of KRW 203.40 billion. The enterprise value is 209.41 billion.

Market Cap	203.40B
Enterprise Value	209.41B

Important Dates

The next estimated earnings date is Thursday, March 26, 2026.

Earnings Date	Mar 26, 2026
Ex-Dividend Date	n/a

Share Statistics

L&K Biomed has 22.35 million shares outstanding. The number of shares has decreased by -6.57% in one year.

Current Share Class	22.35M
Shares Outstanding	22.35M
Shares Change (YoY)	-6.57%
Shares Change (QoQ)	+4.45%
Owned by Insiders (%)	11.87%
Owned by Institutions (%)	0.37%
Float	19.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.23
PB Ratio	5.26
P/TBV Ratio	4.58
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 63.51, with an EV/FCF ratio of -12.41.

EV / Earnings	-12.85
EV / Sales	5.38
EV / EBITDA	63.51
EV / EBIT	n/a
EV / FCF	-12.41

Financial Position

The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.50.

Current Ratio	1.60
Quick Ratio	0.65
Debt / Equity	0.50
Debt / EBITDA	5.47
Debt / FCF	-1.14
Interest Coverage	0.23

Financial Efficiency

Return on equity (ROE) is -44.98% and return on invested capital (ROIC) is 1.35%.

Return on Equity (ROE)	-44.98%
Return on Assets (ROA)	0.54%
Return on Invested Capital (ROIC)	1.35%
Return on Capital Employed (ROCE)	1.58%
Weighted Average Cost of Capital (WACC)	8.57%
Revenue Per Employee	385.35M
Profits Per Employee	-161.35M
Employee Count	101
Asset Turnover	0.47
Inventory Turnover	0.23

Taxes

Income Tax	-353.85M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +33.78% in the last 52 weeks. The beta is 0.72, so L&K Biomed's price volatility has been lower than the market average.

Beta (5Y)	0.72
52-Week Price Change	+33.78%
50-Day Moving Average	12,539.40
200-Day Moving Average	9,717.30
Relative Strength Index (RSI)	30.20
Average Volume (20 Days)	379,044

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, L&K Biomed had revenue of KRW 38.92 billion and -16.30 billion in losses. Loss per share was -802.00.

Revenue	38.92B
Gross Profit	32.02B
Operating Income	715.12M
Pretax Income	-17.15B
Net Income	-16.30B
EBITDA	3.50B
EBIT	715.12M
Loss Per Share	-802.00

Balance Sheet

The company has 6.29 billion in cash and 19.15 billion in debt, with a net cash position of -12.86 billion or -575.43 per share.

Cash & Cash Equivalents	6.29B
Total Debt	19.15B
Net Cash	-12.86B
Net Cash Per Share	-575.43
Equity (Book Value)	38.63B
Book Value Per Share	2,149.90
Working Capital	22.84B

Cash Flow

In the last 12 months, operating cash flow was -13.88 billion and capital expenditures -2.99 billion, giving a free cash flow of -16.87 billion.

Operating Cash Flow	-13.88B
Capital Expenditures	-2.99B
Depreciation & Amortization	2.78B
Net Borrowing	1.71B
Free Cash Flow	-16.87B
FCF Per Share	-754.78

Margins

Gross margin is 82.28%, with operating and profit margins of 1.84% and -41.87%.

Gross Margin	82.28%
Operating Margin	1.84%
Pretax Margin	-44.05%
Profit Margin	-41.87%
EBITDA Margin	8.99%
EBIT Margin	1.84%
FCF Margin	n/a

Dividends & Yields

L&K Biomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	6.57%
Shareholder Yield	6.57%
Earnings Yield	-8.01%
FCF Yield	-8.29%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

L&K Biomed has an Altman Z-Score of 2.3 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.3
Piotroski F-Score	3